NCT05694884

Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 75 (estimated)
• Sponsor: ASLAN Pharmaceuticals · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	Placebo	Placebo Comparator
DRUG	ASLAN004	ASLAN004

Timeline

• Start date: 2022-12-21
• Primary completion: 2024-12-31
• Completion: 2025-02-28
• First posted: 2023-01-23
• Last updated: 2024-01-18

Locations

27 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study